Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

START-J: SiTAgliptin in eldeRly Trial in Japan (START-J)

This study has been completed.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Japan Association for Diabetes Education and Care Identifier:
First received: August 16, 2010
Last updated: March 31, 2015
Last verified: March 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2015
  Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)